Fact of Medicine
Brand Name: Brukinsa
Innovator Brand Name: Brukinsa
API: Zanubrutinib
Packaging: 120 Capsules
Strength: 80mg
Manufacturer Name: BeiGene, Ltd

Get Price


Zanubrutinib Medication

Brukinsa (Zanubrutinib) is a kinase inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Dosage: The recommended zanubrutinib dose is 160mg administered by mouth twice a day or 320mg administered by mouth once daily until the disease is progressive or unacceptable toxicity occurs. Zanubrutinib can be taken with or without food. Patients are advised to swallow capsules whole with water, without being opened, broken, or chewed. If a dose of zanubrutinib is forgotten or missed, it should be administered promptly on the same day with a return to the normal schedule the following day.

Side Effects: The most commonly reported zanubrutinib side effect include:

  • Rash
  • Bruising
  • Diarrhea
  • Cough
  • Neutrophil count decreased
  • Platelet count decreased
  • Upper respiratory tract infection
  • White blood cell count decreased
  • Hemoglobin decreased

Warnings and Precautions:

  • Monitor patients with zanubrutinib 80 mg for signs/symptoms of bleeding. Discontinue therapy in occurrence of intracranial hemorrhage of any grade.
  • Monitor and evaluate patients with zanubrutinib for fever or other signs and symptoms of infection and treat promptly.
  • Monitor patients with zanubrutinib 80 mg for complete blood counts during therapy and treat using growth factor or transfusions, as required.
  • Patients with the therapy of brukinsa should be monitored for signs or symptoms of atrial fibrillation and atrial flutter and should be managed as appropriate.
  • Pregnancy testing is recommended for females of reproductive age prior to starting brukinsa 80 mg therapy. Women are advised to avoid becoming pregnant while on the therapy with brukinsa and for at least 7 days after the last dose.
  • Men are advised to avoid fathering a child while on Brukinsa therapy and for at least 7 days following the last dose.
  • Due to the potential for serious side effects from brukinsa 80 mg in a breastfed child, lactating women are advised not to breastfeed while on therapy and for at least 14 days after the last dose.

More info

Storage: Brukinsa (Zanubrutinib) comes in a bottle with a child-resistant cap. Store the capsules at room temperature between 68°F to 77°F (20°C to 25°C). Keep Zanubrutinib and all medication out of the reach of children. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the BRUKINSA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the BRUKINSA Capsules. Buying Procedure: In order to buy BRUKINSA, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: along with the legitimate ID Proof, standard Prescription and Medical Reports. Conclusion: Treatment with Zanubrutinib was shown to be highly active in patients with Mantle Cell Lymphoma. Zanubrutinib therapy is shown to be generally well-tolerated, with minimal adverse reactions.


What is Brukinsa? Brukinsa is a prescription drug introduced for treating adult patients with mantle cell lymphoma (MCL) who have earlier received at least a single therapy for their cancer. What does Brukinsa contain as an active substance? The medication Brukinsa specifically contains the active substance Zanubrutinib. Is Zanubrutinib an FDA approved drug? Yes, Zanubrutinib is an FDA approved drug. How much does brukinsa cost? The brukinsa price in India usually may vary depending on the wholesaler/pharmacy you visit and of course the brand you choose. What is the best price for Zanubrutinib? Please contact Toll-free: +91 1800 889 1064|+919310090915 for zanubrutinib price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Brukinsa (Zanubrutinib) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Brukinsa (Zanubrutinib), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.